CIBISATAMAB

UNII:	ZAM5J1ATF2
Type:	INGREDIENT SUBSTANCE
Formula:
Preferred Substance Name:	CIBISATAMAB
GSRS Full Record:	ZAM5J1ATF2 i

2101242-53-7
ANTI-CEA/CD3 BISPECIFIC ANTIBODY RO6958688
CEA CD3 TCB
CIBISATAMAB [USAN]
Cibisatamab [WHO-DD]
HUMANIZED IMMUNOGLOBULIN G1 (IGG1) T-CELL BISPECIFIC (TCB) ANTIBODY TARGETING CARCINOEMBRYONIC ANTIGEN (CEA) AND CD3 EPSILON CHAIN (CD3E) ON T-CELLS
IMMUNOGLOBULIN G1, HUMANIZED BISPECIFIC TRIVALENT, ANTI-(HUMAN CARCINOEMBRYONIC ANTIGEN/HUMAN CD3 ANTIGEN .EPSILON.-CHAIN) BIVALENT .GAMMA.-CHAIN, DISULFIDE WITH ANTI-(HUMAN CARCINOEMBRYONIC ANTIGEN) .KAPPA.-CHAIN, ANTI-(HUMAN CARCINOEMBRYONIC ANTIGEN) MONOVALENT .GAMMA.-CHAIN AND ANTI-(HUMAN CD3 ANTIGEN .EPSILON.-CHAIN) .KAPPA.-CHAIN
IMMUNOGLOBULIN G1-KAPPA/LAMBDA WITH DOMAIN CROSSOVER, ANTI-(HOMO SAPIENS CARCINOEMBRYONIC ANTIGEN-RELATED CELL ADHESION MOLECULE 5 (CD66E ANTIGEN)) AND ANTI-(HOMO SAPIENS T-CELL SURFACE GLYCOPROTEIN CD3 EPSILON CHAIN (CD3E ANTIGEN)) HUMANIZED MONOCLONAL ANTIBODY, BISPECIFIC, TRIVALENT .GAMMA.-.KAPPA. HEAVY CHAIN ANTI-HUMAN CARCINOEMBRYONIC ANTIGEN AND CD3E ANTIGEN (VH-CH1-VH-C-KAPPA-CH2-CH3) (1-694) (HUMANIZED VH ANTI-CARCINOEMBRYONIC ANTIGEN (HOMO SAPIENS IGHV1-18*01 (83%) (IGHD)-IGHJ4*01 (92%)) (8.8.14) (1-121)-HOMO SAPIENS IGHG1*01 (CH1-HINGE-(1-6))(122-225) BIS(TETRAGLYCYL-SERYL) (226-235) HUMANIZED VH ANTI-CD3E ANTIGEN (HOMO SAPIENS IGHV3-23*03 (87%) (IGHD)-IGHJ6*01 (91%)) (8.10.16) (236-360)-HOMO SAPIENS IGKC*01(R1>A(361),T2>S(362)) (361-467)-HOMO SAPIENS IGHG1*01(HINGE-(6-15), CH2(L4>A(481),L5>A(482),P99>G(576)), CH3(S14>C(601),T26>W(613))) (468-694)) (224-215')-DISULFIDE WITH .KAPPA. LIGHT CHAIN ANTI-HUMAN CARCINOEMBRYONIC ANTIGEN (1'-215') (HUMANIZED V-KAPPA (HOMO SAPIENS IGKV1-16*01 (82%) IGKJ2*02)(6.3.10) (1'-108')-HOMO SAPIENS IGKC*01 (109'-215')) (467-214'')-DISULFIDE WITH .LAMBDA.-.GAMMA. LIGHT CHAIN AND CD3E ANTIGEN (1''-214'') (V-LAMBDA (MUS MUSCULUS IGLV1*01 (81%) IGKJ1*01)(9.3.9) (1''-109'') BISERYL (110''-111'') HOMO SAPIENS IGHG1*01 (CH1-HINGE(1-5))(112''-214'')) .GAMMA.1 HEAVY CHAIN ANTI-HUMAN CARCINOEMBRYONIC ANTIGEN (1'''-451''') (HUMANIZED VH (HOMO SAPIENS IGHV1-18*01 (83%) (IGHD)-IGHJ4*01 (92%)) (8.8.14) (1'''-121''')-HOMO SAPIENS IGHG1*01 (CH2(L4>A(238),L5>A(239),P99>G(333)), CH3(Y9>C(353),T26>S(370),L28>A(372),Y67>V(411))) (122'''-451''')) (224'''-215'''')-DISULFIDE WITH .KAPPA. LIGHT CHAIN ANTI-HUMAN CARCINOEMBRYONIC ANTIGEN (1''''-215'''') (HUMANIZED V-KAPPA (HOMO SAPIENS IGKV1-16*01 (82%) IGKJ2*02)(6.3.10) (1''''-108'''')-HOMO SAPIENS IGKC*01 (109''''-215'''')), DIMER (230'''-473: 233'''-476: 353'''-601)-TRISDISULFIDE
RG7802
RO-6958688
RO6958688
cibisatamab [INN]

Note

UNIIs are generated based on scientific identity characteristics using ISO 11238 data elements. UNII availability does not imply any regulatory review or approval. Synonyms and mappings are based on the best public information available at the time of publication. Please report any problems/errors associated with this data to FDA-SRS@fda.hhs.gov.

CIBISATAMAB

Synonyms and Mappings

Resources